Provided by Tiger Trade Technology Pte. Ltd.

Sunshine Biopharma Inc.

0.8998
+0.05876.98%
Post-market: 0.8900-0.0098-1.09%19:31 EDT
Volume:157.77K
Turnover:135.77K
Market Cap:3.49M
PE:-0.09
High:0.8999
Open:0.8200
Low:0.8200
Close:0.8411
52wk High:24.30
52wk Low:0.8200
Shares:3.88M
Float Shares:3.81M
Volume Ratio:1.07
T/O Rate:4.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0329
EPS(LYR):-14.3739
ROE:-21.92%
ROA:-9.91%
PB:0.13
PE(LYR):-0.06

Loading ...

Sep 16, 2026

Major Issues Report

Form 8-K - Current report
Sep 11, 2026

Major Issues Report

Form 8-K - Current report
Aug 28, 2026

Major Issues Report

Form 8-K - Current report
Aug 28, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Aug 14, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 03, 2026

Major Issues Report

Form 8-K - Current report
Jul 20, 2026

Major Issues Report

Form 8-K - Current report
Jul 10, 2026

Major Issues Report

Form 8-K - Current report
Jul 08, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 29, 2026

Major Issues Report

Form 8-K - Current report
May 22, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 22, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 20, 2026

Major Issues Report

Form 8-K - Current report
May 18, 2026

Correspondence

Form CORRESP - Correspondence
May 18, 2026

Correspondence

Form CORRESP - Correspondence
May 15, 2026

Correspondence

Form CORRESP - Correspondence
May 15, 2026

Correspondence

Form CORRESP - Correspondence
May 13, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]